D-0120 is under clinical development by InventisBio and currently in Phase II for Hyperuricemia. According to GlobalData, Phase II drugs for Hyperuricemia have a 31% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how D-0120’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
D-0120 is under development for the treatment of hyperuricemia and gout. It is administered orally in the form of a tablet. It acts by targeting uric acid transporter 1 (URAT1).
InventisBio is a biotechnology company focused on discovery and development of novel therapeutics in the areas of oncology and metabolic diseases. The company is headquartered in Shanghai, China.
For a complete picture of D-0120’s drug-specific PTSR and LoA scores, buy the report here.